24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Long-Term Outlook for Most With Serious Brain Injury Is Better Than ThoughtDrug Shows Promise in Easing Dementia-Linked PsychosisAHA News: Diabetes and Dementia Risk: Another Good Reason to Keep Blood Sugar in Check1 in 20 Cases of Dementia Occurs in People Under 65Could Menopausal Hormone Therapy Reduce Women's Odds for Dementia?Reading, Puzzles May Delay Alzheimer's by 5 Years: StudyTwo Major Health Systems Won't Administer Controversial New Alzheimer's DrugMost Marriages Survive a Spouse's Brain InjuryMedicare Mulls Coverage for Controversial Alzheimer's DrugFDA Head Asks for Investigation Into Alzheimer's Drug ApprovalNew Prescribing Instructions Tighten Use of Controversial Alzheimer's DrugMissing Teeth, Higher Odds for Dementia?AHA News: Smoking Harms the Brain, Raises Dementia Risk – But Not If You QuitHealthy Living Can Lower Your Odds for Alzheimer'sKeeping Same Nurse for All Home Health Care May Be Crucial for Dementia PatientsMost Cases of Dementia in U.S. Seniors Go Undiagnosed: StudyLilly to Seek FDA Approval for New Alzheimer's DrugCould a Type of Statin Raise Dementia Risks?Good News, Bad News From Alzheimer's Vaccine TrialPoor Sleep After Head Injury Could Point to Dementia RiskFDA Approves Alzheimer's Drug Despite Expert Panel's ObjectionsFDA Defends Approval of Controversial Alzheimer's DrugPeople of Color Have Twice the Risk of Dying After Brain Injury, Study FindsIn People With Type 1 Diabetes, Poor Blood Sugar Control Could Raise Dementia RiskThere's Been a Shift in Who's Funding Alzheimer's ResearchHealthy Living Helps Prevent Dementia, Even If It Runs in the FamilyAHA News: Is It Normal Aging or Early Signs of Dementia?Failing Kidneys Could Bring Higher Dementia RiskDementia Risk Rises as Years Lived With Type 2 Diabetes IncreasesHead Injury, Alzheimer's Appear to Affect Brain in Similar WaysBrain Injuries Raise Long-Term Risk of StrokeResearch Shows Links Between Gum Disease and Alzheimer'sAssisted Living Centers Can Do More for Dementia Patients, Experts SayDiminished Hearing, Vision Together Could Be Risk Factor for Dementia6 Steps to Reduce Caregiver StressLoneliness in Mid-Life Linked to Higher Odds for Alzheimer'sDrug Used in Cancer Patients Might Help Treat Alzheimer's'Non-Drug' Approaches Can Fight Depression in People With DementiaSuicide Attempts Spike Soon After Dementia DiagnosisCould a New Drug Help Ease Alzheimer's?AHA News: Dementia May Be a Risk Factor for Infection But Not Death From COVID-19Your Eyes May Signal Your Risk for Stroke, DementiaEven 1 Concussion May Raise Your Odds for Dementia LaterAlzheimer's Patients Are Being Given Too Many MedsMany Blacks, Hispanics Believe They'll Get Worse Care If Dementia StrikesAlzheimer's May Strike Women and Men in Different WaysHistory of Mental Illness Tied to Earlier Onset of Alzheimer's DiseaseAHA News: Black, Hispanic Families Hit Hardest by DementiaWhy Some 'Super Ager' Folks Keep Their Minds Dementia-FreeDementia Seen in Younger Adults Shows Even More Brain Damage Than Alzheimer's
Questions and AnswersLinks
Related Topics

New Prescribing Instructions Tighten Use of Controversial Alzheimer's Drug

HealthDay News
by Robert Preidt
Updated: Jul 8th 2021

new article illustration

THURSDAY, July 8, 2021 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday issued new prescribing rules for the controversial Alzheimer's medication Aduhelm that will likely limit its use.

When first approved a month ago, the FDA said Biogen's monthly IV drug was for all Alzheimer's patients. The agency now says the drug is appropriate for patients with early or mild Alzheimer's but that it has not been studied in patients with more advanced disease, the Associated Press reported.

The change is meant to end confusion among physicians and patients about who should get the drug, according to the agency.

Such major changes to prescribing instructions are rare, especially so soon after approval, and this change could curb the drug's use, the AP reported. While doctors may still prescribe the drug for patients with advanced disease, insurers might refuse to pay for it.

Still, the FDA added that "some patients may benefit from ongoing treatment" if they progress to more advanced Alzheimer's.

"It was pretty troubling that the previous label was so broad and included groups of patients in whom the drug had never been tested," Dr. Suzanne Schindler, of Washington University in St. Louis, told the AP. "I think this is a positive change, because it better reflects the patients in whom the drug was actually studied."

The drug's approval and its $56,000-a-year price tag have been heavily criticized. An FDA advisory panel voted against approval of the drug, and three members resigned after the FDA approved it. One of them, a leading Harvard University expert, said it was the "worst drug approval decision in recent U.S. history."

There's no evidence that the drug reverses or significantly slows Alzheimer's, but the FDA said that its ability to reduce clumps of amyloid plaque in the brain is likely to slow dementia. However, there is little evidence to support that claim, many experts say.

Under the FDA approval, Biogen must conduct a follow-up study to confirm if the drug actually slows mental decline.

Two House committees have launched an investigation into the FDA's review of the drug, and Senate lawmakers have called for hearings into the drug's cost and impact on federal spending, the AP reported.

About 6 million Americans have Alzheimer's and the vast majority qualify for Medicare coverage. There are worries that Aduhelm could put a huge financial strain on Medicare, the AP said.

More information

Visit the Alzheimer's Association for more on Alzheimer's disease.

SOURCE: Associated Press